載入中
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
前收盤價
US$59.86
+US$0.84 · +1.42%
盤中時間採用ET。市場資料可能有所延遲。
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
日內區間
目前US$59.86
52週區間
目前US$59.86
盤中時間採用ET。市場資料可能有所延遲。
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
日內區間
目前US$59.86
52週區間
目前US$59.86
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 23.2億 USD | 21.69億 USD | 18.3億 USD | 16.11億 USD | 14.35億 USD |
| 銷貨成本 | 8369.7萬 USD | 7621.6萬 USD | 7254.7萬 USD | 5790.9萬 USD | 5287.3萬 USD |
| 毛利 | 22.36億 USD | 20.92億 USD | 17.58億 USD | 15.53億 USD | 13.82億 USD |
| 研究與開發 | 8.25億 USD | 9.1億 USD | 10.44億 USD | 8.92億 USD | 6.94億 USD |
| 銷售、一般及管理費用 | 5.19億 USD | 4.92億 USD | 5.43億 USD | 4.6億 USD | 4.02億 USD |
| 營業費用 | 13.64億 USD | 14.88億 USD | 15.87億 USD | 13.52億 USD | 10.95億 USD |
| 利息收入 | 6921.3萬 USD | 7715.6萬 USD | 8654.3萬 USD | 3306.5萬 USD | 767.2萬 USD |
| 折舊和攤銷 | 2905.5萬 USD | 2880.3萬 USD | 2571.7萬 USD | 2087.5萬 USD | 1363萬 USD |
| 營業利益 | 8.72億 USD | 6.05億 USD | 1.71億 USD | 2.01億 USD | 2.87億 USD |
| 淨利 | 7.83億 USD | 5.21億 USD | 2.08億 USD | 1.82億 USD | 2.31億 USD |
公司資料更新於 2026年10月11日。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$52.33
下跌空間 12.58%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4.15億0.02%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Morningstar Small-Cap ETFVB3億0.16%1853億 USD0.03%US$289.48+0.64%
Invesco S&P MidCap Quality ETFXMHQ1.84億3.38%54.37億 USD0.30%US$114.23+0.50%
Vanguard Morningstar Small-Cap Growth ETFVBK1.72億0.38%447億 USD0.05%US$344.74+1.22%
Vanguard Extended Market ETFVXF1.6億0.16%954億 USD0.05%US$235+0.80%
State Street SPDR S&P Biotech ETFXBI1.52億1.53%98.74億 USD0.35%US$153.77+3.00%
iShares Biotechnology ETFIBB1.1億1.04%108.2億 USD0.44%US$206.49+3.00%
State Street SPDR S&P MIDCAP 400 ETF TrustMDY1.09億0.42%258.17億 USD0.23%US$669.87+0.54%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBInvesco S&P MidCap Quality ETFXMHQVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFState Street SPDR S&P Biotech ETFXBIiShares Biotechnology ETFIBBState Street SPDR S&P MIDCAP 400 ETF TrustMDYAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
